

RESEARCH

Open Access



# The influence of *PER3* VNTR genotypes on the age of onset in a group of bipolar I disorder patients: an exploratory study

Tommaso Barlattani<sup>1\*</sup>, Bettina Soltmann<sup>2</sup>, Chiara D'Amelio<sup>1</sup>, Valentina Socci<sup>1</sup>, Francesca Pacitti<sup>1</sup>, Maurizio Pompili<sup>3</sup> and Philipp Ritter<sup>2</sup>

## Abstract

**Background** *PER3* is a circadian gene that contains a variable number of tandem repeats (VNTR) which codifies for three genotypes: 4/4; 4/5; and 5/5 and is involved in non-visual response to light, a critical process associated with bipolar disorder onset. Benedetti et al. (*Neurosci Lett* 445(2):184–7) related this VNTR with bipolar disorder age of onset and linked genotype 5/5 with an earlier onset. In this study, we aimed to investigate these associations of *PER3* VNTR genotypes with age of onset in a homogenous sample of German patients with bipolar I disorder through Kaplan-Meier curves.

**Methods** 45 patients were enrolled and divided into three groups according to *PER3* VNTR genotypes. Recognizing common biological features, we built a combined group of -5 allele carriers (4/5 + 5/5). As a primary outcome, Kaplan-Meier analysis was conducted to delineate the three genotypes' influence on age of onset. The secondary Kaplan-Meier analysis aimed to evaluate the relation between the 4/4 homozygotes group and the combined group (4/5 + 5/5) with age of onset. Finally, we proceeded to compare groups through a Log Rank Test and performed an analysis of covariance (ANCOVA).

**Results** The Kaplan-Meier analysis with three separate genotypes didn't replicate the findings of Benedetti's study. The analysis comparing genotype 4/4 with the combined group showed the influence of *PER3* VNTR variants on the age of onset and relates genotype 4/4 to an earlier onset. ANCOVA between the combined and the 4/4 genotype groups, correlated genotype 4/4 with an increased number of depressive episodes.

**Conclusion** This study showed no significant effect of *PER3* VNTR genotypes on the age of onset and in linking genotype 5/5 with an earlier onset age. Contrasting results may arise from intrinsic differences between the two studies but also shed light on hypothetically different levels of functioning of *PER3* VNTR genotypes in the context of bipolar pathology. Further studies will require bigger and more homogeneous clinical samples.

**Keywords** Bipolar disorder, Age of onset, *PER3* VNTR, Kaplan-Meier, Melanopsin

\*Correspondence:  
Tommaso Barlattani  
tbarlattani@gmail.com

<sup>1</sup>Chair of Psychiatry, Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, Via Vetoio, Coppito 2, L'Aquila 67100, Italy

<sup>2</sup>Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

<sup>3</sup>Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Unit of Psychiatry, Sapienza University, Sant'Andrea University Hospital, Rome, Italy



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## Background

The utility of the age of onset, namely the age at which the patient first met criteria for a mood episode (manic, hypomanic, depressive or mixed), as a parameter for a better definition and understanding of bipolar and related disorders has been widely discussed (Leboyer et al. 2005). Moreover, bipolar patients often experience subthreshold symptoms before the onset age of the disease (Van Meter et al. 2016). Furthermore, when approaching bipolar disorder's age of onset, gene-related parameters have been proven of utmost importance. A study conducted by Bellivier et al. (2001) and then reproduced in different samples (Hamshere et al. 2009; Manchia et al. 2008) identified three different onset groups and a polygenic non-Mendelian transmission was suggested for the early onset disease (Grigoriou-Serbanescu et al. 2001). An earlier onset has an impact on the course of the illness (Propper et al. 2015; Subramanian et al. 2018) and has been related to a positive family history of bipolar disorder (Post et al. 2014). However, the lack of a clear association between single nucleotide polymorphisms and the age of onset, even when approaching homogenous samples, such as early-onset patients, suggests that the development and course of the illness are thereby influenced by genetic and environmental factors (Kalman et al. 2019).

A study conducted by Bauer et al. in 2012 observed an inverse relationship between the greatest solar insolation in spring, depending on latitude, and the age of onset, hypothesizing the role of regulatory genes in patients' response to light. Light is recognized as the strongest external zeitgeber capable of synchronizing our core clock, the suprachiasmatic nucleus (SCN) (Roenneberg et al. 2007). Thanks to the blue-light sensitive melanopsin photopigment, the internal photosensitive retinal ganglion cells (ipRGC) can process environmental light by modulating the non-visual response to light (Hattar et al. 2002). These cells project to the SCN providing signals that determine the harmonization of the circadian cycle with the external environment (Lax et al. 2019).

Bipolar disorder appears to be associated with circadian alterations and the role of a disrupted harmony in circadian rhythms, such as alterations in the sleep architecture (Ritter et al. 2015) or impaired melatonin secretion (Etain et al. 2012), has been documented in the context of the pathology. The strong association with eveningness (Mansour et al. 2005) and the finding of a circadian disruption even in drug-naïve patients (Melo et al. 2017), has contributed to the identification of these as characteristic traits of the pathology, rather than episode's dependent alterations, thus implying a possible genetic explanation. Our circadian clock responds to external cues, while internal zeitgebers are represented by circadian genes, that are regulated endogenously with feedback-loops mechanisms (Abreu and Bragança 2015).

*PER3* is a circadian gene of the period family expressed in the SCN (Archer et al. 2018). In humans, *PER3* dimerizes with *PER1*, *PER2* and *CRY1*, *CRY2* proteins inhibiting the *CLOCK BMAL1* complex and contributing to the maintenance of circadian period length (Matsumura and Akashi 2019). Variants of *PER3* have been associated with bipolar disorder (Mansour et al. 2006; Nievergelt et al. 2006; Brasil Rocha et al. 2017). Its coding region presents a variable number of tandem repeats (VNTR) on exon 18 with a sequence of 54 base pairs repeated 4 or 5 times, identifying 3 distinct genotypes: homozygous 4/4, heterozygous 4/5, and homozygous 5/5 (Ebisawa et al. 2001). The association of *PER3* VNTR genotypes with morningness or eveningness and a pathological condition such as delayed sleep phase syndrome (DSPD) confirmed that the number of repeated regions could influence the phosphorylation levels, affecting the gene's functioning (Archer et al. 2003). A study conducted by Leocadio-Miguel et al. (2018) showed how *PER3* VNTR variants could regulate sleep-wake behavior with differences that appear to be related to latitude. Noticeably, this polymorphism modulates non-visual responses to light (Chellappa et al. 2014) by influencing the alerting response, melatonin suppression (Chellappa et al. 2012) and cognitive properties (Vandewalle et al. 2011).

Variants of *PER3* have been associated with bipolar disorder (Mansour et al. 2006; Nievergelt et al. 2006; Brasil Rocha et al. 2017). In this context, the VNTR polymorphism of *PER3* might influence the white matter integrity (Bollettini et al. 2017), the postpartum onset of the disease (Dallaspazia et al. 2011), the antidepressant effect of sleep deprivation (Dallaspazia et al. 2016) and the age of onset of the disease (Benedetti et al. 2008; Karthikeyan et al. 2014). The research conducted by Benedetti investigated the impact of *PER3* VNTR polymorphisms on the age of onset in a group of 99 patients diagnosed with bipolar I disorder through a Kaplan-Meier analysis. Results from Benedetti's study indicated an association of *PER3* VNTR genotypes with the age of onset of bipolar disorder and correlated genotype 5/5 with an earlier onset. Several works (Alexander et al. 2015; Dai et al. 2011; Guess et al. 2009; Yamaguchi et al. 2015; Wirth et al. 2014; Drake et al. 2015; Zhu et al. 2005; Viena et al. 2016) considered 4/5 and 5/5 genotypes as a single entity, thus focusing on common biological features and possible differences associated with the presence of the -5 allele.

With the present study, we aimed to confirm the suggested association of *PER3* VNTR genotypes with age of onset in an independent sample of 45 German patients diagnosed with bipolar I disorder. Our primary goal was to evaluate the age of onset, defined as the first episode in which the patient meets the criteria for an affective episode, about the three separate genotypes of *PER3* VNTR.

Secondarily, we explored a potential relation between the 4/4 homozygotes group and a combined group of -5 allele, both in hetero- and homozygosis (4/5+5/5) and their influence on age of onset, to focus on differences associated exclusively with the presence of the -5 allele. Other secondary aims focused on assessing the relationship between *PER3* VNTR variants with the age of symptoms onset, thus including subthreshold symptoms, the polarity of onset (i.e., depressive, hypo-/manic or mixed first mood episode) and, finally, the number of episodes and suicide attempts.

## Methods

### Participants

The sample included 45 patients (21 males, 24 females) diagnosed with bipolar I disorder according to DSM-V criteria, which were in a euthymic phase at the time of the study. The recruited patients were already selected as samples for two separate chronobiology studies published elsewhere (Ritter et al. 2019, 2020).

The study was approved by the institutional review board of the Medical Faculty of the Technische Universität Dresden (IRB00001473 and IORG0001076).

We enrolled patients with bipolar I disorder from the outpatient departments of 4 different hospitals in Dresden and the nearby area, as well as by advertisement in local newspapers and websites of bipolar advocacy groups between 2016/2017. The age range was restricted to patients aged between 18 and 60 years of age. The study was conducted during the winter months (November 2015 to March 2016; November 2016 to March 2017) at latitude 51°N.

Written informed consent was obtained from all patients willing to participate in the study after a detailed description of the study's aim and procedures. An experienced psychiatrist from our local psychiatric department assessed, employing accurate procedures, age of onset, age of first symptoms manifestation (including subthreshold symptomatology), number of depressive/manic/hypomanic or mixed episodes, number of manic episodes with psychotic features, hospitalizations, number of compulsory treatment or forced admission and the presence, and eventually the number, of suicide attempts. Age of onset was defined as the first episode that met the criteria for a hypo- /-manic, mixed or depressive episode as defined by DSM-V.

According to previous research underlining common biological features associated with the presence of the -5 allele (Alexander et al. 2015; Dai et al. 2011; Guess et al. 2009; Yamaguchi et al. 2015; Wirth et al. 2014; Drake et al. 2015; Zhu et al. 2005; Viena et al. 2016), we built a combined group of -5 allele hetero- and homozygotes (4/5+5/5). Finally, to clarify the effect of 4/4 homozygotes and a combined group of -5 allele hetero- and

homozygotes (4/5+5/5) on the age of onset, we performed a Kaplan-Meier analysis.

### Laboratory procedures

A blood sample was collected in 9 mL clotting tubes containing EDTA (S-Monovette K3, Sarstedt) for the genetic analyses. After centrifugation of the clotting tubes at 1000 g for 15 minutes, the EDTA whole blood was stored at -80°C until the analyses were performed. Genomic DNA was extracted from frozen (-80°C) EDTA whole blood using a QIAmp DNA blood mini kit (Qiagen) according to the manufacturer's protocol. To quantify and assess the purity of the DNA, the absorbance at 260 nm and the ratios A 260/280 and A 260/230 were measured using a NanoDrop © 2000 spectrophotometer (Thermo Fisher). Polymerase chain reaction (PCR) was then performed with the following primers: 5'TGTCTTTTCATGTGCCCTTACTT-3' and 5'TGTCTGGCATTGGAGTTTGA-3'. The PCR reaction was carried out in a 25 µL volume containing 150 ng DNA, 0.5 µM of each primer, 200 µM deoxynucleoside triphosphate, 1 × Q5 reaction buffer and 0.02 U/µL Q5 high-fidelity DNA polymerase (New England Biolabs). After an initial step of 30 s at 98 °C, 30 cycles of amplification (10 s at 98 °C, 30 s at 65 °C, 25 s at 72 °C) and a final elongation step of 5 min at 72 °C were performed. An aliquot of PCR product was analyzed on agarose (2% agarose LE, Biozym) gel electrophoresis (5 V/cm for 90 min) to distinguish between the -5 repeat allele (401 bp), the 4 repeat allele (347 bp) and the heterozygotes (347 and 401 bp).

### Statistical analysis

We built cross tables for the description of sociodemographic and clinical data and then proceeded to calculate mean values, standard deviation, and frequencies for each variable considered. A chi-square test was conducted to evaluate whether the sample was in Hardy-Weinberg equilibrium. As the primary outcome, Kaplan-Meier analysis was performed to assess the potential influence of the three genotype subgroups (*PER3* 4/4; *PER3* 4/5; *PER3* 5/5) on the age of onset.

Analysis was carried out on three curves each for the single genotypes considered and then comparison between the groups was conducted through a Log Rank Test.

As a secondary outcome, according to previously demonstrated common biological features, we combined groups of -5 allele hetero- and homozygotes (4/5+5/5). Aiming to clarify the effect of 4/4 homozygotes and the combined group of -5 allele in hetero- and homozygosis (4/5+5/5) on the age of onset, we performed a Kaplan Meier analysis. We constructed two curves for the two groups. We then proceeded to perform a Log Rank Test to compare the two groups.

Kaplan-Meier analysis was conducted for the age of symptomatic onset including subthreshold symptoms, age at the first depressive episode and age at first hypo-/manic episode concerning the aforementioned groups, both separate and combined. Groups were compared through a Log Rank test for all the analyses mentioned.

Finally, we carried out univariate analysis of covariance ANCOVA for group comparisons of different variants such as number of depressive, manic (manic plus hypomanic) and mixed episodes, number of depressive and manic episodes with psychotic symptoms, number of inpatient stays, number of forced admissions or compulsory treatments, and number of suicide attempts, all of which were adjusted for the duration of the illness. The analysis included age at onset as a covariate. For the analyses carried out, we defined statistical significance as demonstrated by a P-value of less than 0.05. Statistical analysis was conducted using IBM SPSS statistics for Windows, version 26.

## Results

### Primary outcome: age of onset

The average age of onset was (mean  $\pm$  standard deviation) 21,84  $\pm$  9,322.

Observed genotype frequencies were: *PER3* 4/4 17/45 (37.8%), *PER3* 4/5 21/45 (46.7%), *PER3* 5/5 7/45 (15.5%).

The sample was in Hardy-Weinberg equilibrium as confirmed by the Chi-square test ( $\chi^2=0.15$ ,  $p=0.993$ ).


The Kaplan-Meier analysis was conducted to determine the influence of *PER3* VNTR variants on the age of onset for the three separate genotypes. Although 5/5 homozygotes presented a later age of onset when compared to both heterozygotes and 4/4 homozygotes, reported differences were not statistically significant (Fig. 1; Table 1).

Results of the Kaplan-Meier analysis, performed for the 4/4 and the combined group of 4/5 and 5/5 genotypes, demonstrated an influence of both groups on the age of onset, namely an association with an earlier onset, as demonstrated by an average age of 18,588  $\pm$  1,55, for the 4/4 homozygotes and an average age of 23,821  $\pm$  1,95 for the combined group confirmed by statistical evidence, P-value= 0,027, in the Log Rank Test (Fig. 2; Table 2).

### Secondary outcomes

The Kaplan-Meier analysis was conducted to determine the influence of *PER3* VNTR variants on the three separate genotypes regarding the age of symptomatic onset, the age of the first depressive episode and of the first manic (hypo-/manic) episode, numerically 4/4 homozygosis was associated with an earlier onset when compared to both heterozygosis and 5/5 homozygotes, although reported differences that were not statistically

### Kaplan Meier analysis between genotype 4/4 group, genotype 4/5 group and genotype 5/5 group



**Fig. 1** The lifetime distribution of age at onset in the three genotypic groups

**Table 1** Age of onset according to PER3 VNTR three genotypes

	PER3 VNTR			Log Rank Test P-value
	4/4 (N=17)	4/5 (n=21)	5/5 (n=7)	
Age of onset (mean ± SD)	18,588 ± 1,55	23,619 ± 2,12	24,429 ± 4,86	0,076
Age of first symptoms (mean ± SD)	18,353 ± 1,52	21,905 ± 2,05	25,714 ± 4,71	0,130
Age of the first depressive episode (mean ± SD)	19,467 ± 1,47	23,650 ± 2,32	24,571 ± 1,42	0,219
Age of the first hypo-/manic episode (mean ± SD)	24,059 ± 1,99	27,857 ± 2,04	27,000 ± 4,98	0,395

AbbreviationsVNTR: Variable number tandem repeats; SD: Standard Deviation

significant (Supplementary Fig. 3; Supplementary Fig. 5; Supplementary Fig. 7).

Moreover, analyses carried out for the same parameters but comparing the combined group composed of 4/5 and 5/5 individuals with homozygous individuals for genotype 4/4 reported no statistical significance

**Table 2** Age of onset according to PER3 VNTR 4/4 group and combined group 4/5 + 5/5


	PER3 VNTR		Log Rank Test P-value
	4/4 (n=17)	4/5 + 5/5 (n=28)	
Age of onset (mean ± SD)	18,588 ± 1,55	23,821 ± 1,95	0,027
Age of first symptoms (mean ± SD)	18,353 ± 1,52	22,857 ± 1,91	0,065
Age of the first depressive episode (mean ± SD)	0,219 ± 1,47	23,889 ± 2,09	0,092
Age of the first hypo-/manic episode (mean ± SD)	24,059 ± 1,99	27,643 ± 1,92	0,173

AbbreviationsVNTR: Variable number tandem repeats; SD: Standard Deviation

(Supplementary Fig. 4; Supplementary Fig. 6; Supplementary Fig. 8).

The ANCOVA analysis conducted on the three separate genotypes and adjusted for the duration of illness and with the age of onset as a covariate, showed no statistically significant association with the total amount of depressive episodes, manic (hypo-/manic) episodes, mixed episodes, depressive episodes with psychotic symptoms, manic episodes with psychotic symptoms, number of stationary phases, number of suicide attempts

**Kaplan Meier analysis between genotype 4/4 group and combined 4/5 + 5/5 group**



**Fig. 2** The lifetime distribution of age at onset in the genotype 4/4 group and the 4/5 + 5/5 combined group



and of inpatient stays with none of the genotype taken into account (Supplementary Table 4).

Furthermore, ANCOVA analysis adjusted for the duration of illness and with the age of onset as a covariate, conducted to compare the 4/4 genotype group and the combined 4/5–5/5 group, revealed no statistically significant association with the total amount of manic (hypo-/manic) episodes, mixed episodes, depressive episodes with psychotic symptoms, manic episodes with psychotic symptoms, number of stationary phases, number of suicide attempts and of inpatient stays. Nevertheless, the analysis demonstrated a statistically significant higher number of depressive episodes linked to the 4/4 genotype group, with an average of  $17,59 \pm 23,86$  episodes and  $P\text{-value} = 0,026$  (Table 3).

## Discussion

In the present study, the Kaplan-Meier analysis was conducted to investigate the association of *PER3* VNTR genotypes with age of onset in an independent sample of 45 patients diagnosed with bipolar I disorder. Results showed no significant effect of *PER3* VNTR genotypes on the age of onset and in linking genotype 5/5 with an earlier onset age as demonstrated in Benedetti's previous study.

Despite those differences that could occur by chance, some considerations need to be made.

The first consideration concerns differences between methodologies employed in the two studies for the statistical analysis. Benedetti's group used a two-way ANOVA, with sex and genotype as co-factors, while in our study,

curves of Kaplan-Meier's analysis were compared using the Log Rank test. Another consideration regards differences in characteristics of the groups considered. Particularly, dissimilarities between the two groups are mostly prominent when focusing on the age of onset. Benedetti's sample presented the age of onset comparable to an intermediate onset (mean age of onset  $31,78 \pm 11,18$ ), while our sample's age of onset (mean  $21,84 \pm 9,322$ ) was more congruent with the average of bipolar I disorder, which is around 22 years of age (Goodwin and Jamison 2007). This result could not be justified by a delayed age of onset related to differences in average age between Italy and Germany. Moreover, as previously shown by the study of Bauer et al. (2012), the amount of sunlight exposure is also an important factor whose effect on the onset of the disease must be considered, therefore differences in latitudes between the two countries may be accountable for such discrepancy. But, despite the city of Milan, where Benedetti's study was conducted, being at a latitude of  $45^\circ$  and the city of Dresden is at a latitude of  $51^\circ$ , the difference in slope in a change of solar insolation is unlikely to be substantially different between the two cities. Thus, differences in latitude are probably not accountable for such a delayed onset, which should be therefore regarded as an intrinsic characteristic of the examined group. Differences in capturing this parameter, with such a late onset for Benedetti's sample could have led to skewed results.

As a result of the comparison between the 4/4 genotype group and the combined group presenting the –5 allele, we observed the influence of *PER3* VNTR variants on the age of onset. However, while results from Benedetti's study from 2008 demonstrated an association of the *PER3* 5/5 variant with an earlier onset, data obtained from our study revealed a substantially opposite association. In our study, we found genotype 4/4 to be more commonly associated with an earlier onset of disease. Noticeably, other studies on *PER3* VNTR variants yielded such conflicting results. The study carried out by Pereira et al. (2005) correlated DSPD with *PER3* VNTR genotypes, resulting in radical opposition with previous studies, but in line with our findings as, in the morning immediately after sleep, subjects exposed to blue light with genotype 4/4 exhibit substantially higher activation of parietal and prefrontal areas (Vandewalle et al. 2011). This enhanced response is also supported by evidence of a greater response to the application of supplementary light in the blue wavelength during this part of the day (Turco et al., 2017). The role of morning light in bipolar disorder has been already established when approaching therapeutic options (Benedetti et al., 2001), but may also be significant when focusing on the onset of the disorder in genotypically more light-sensitive subjects during that particular time of the day. Most drastic

**Table 3** Episodes according to *PER3* VNTR 4/4 group and combined group 4/5 + 5/5

	<i>PER3</i> VNTR		ANCOVA P-value
	4/4 (n = 17)	4/5 + 5/5 (n = 28)	
Number of depressive episodes (mean ± SD)	17,59 ± 23,86	8,75 ± 6,73	0,026
Number of hypo- /- manic episodes (mean ± SD)	24,06 ± 8,24	27,64 ± 10,19	0,484
Number of mixed episodes (mean ± SD)	6,50 ± 14,65	3,50 ± 9,42	0,682
Number of manic episodes with psychotic symptoms (mean ± SD)	1,06 ± 2,02	1,21 ± 2,11	0,742
Number of depressive episodes with psychotic symptoms (mean ± SD)	1,71 ± 3,08	0,39 ± 0,79	0,107
Number of inpatient stays (mean ± SD)	1,47 ± 1,50	4,36 ± 4,70	0,058
Number of forced admissions (mean ± SD)	0,53 ± 1,18	0,79 ± 1,40	0,818
Number of suicide attempts (mean ± SD)	0,59 ± 1,18	0,64 ± 1,06	0,794

Abbreviations/VNTR: Variable number tandem repeats; SD: Standard Deviation

changes in light conditions take place during dusk and dawn when the light reflects the blue wavelength (Foster 2005; Dick 2012), these changes are most prominent also during changing of seasons and are also strictly dependent on latitude. Indeed, the sudden fluctuations related to the change of season and to the different light phases during the day affect the subjects carrying these genes more intensely, especially in the morning. Despite the hypothetical character of our observations, it is legitimate to suppose that the conflicting results presented in this study may also derive from a complex interrelation between genetic factors and environmental conditions.

Focusing on the number of depressive episodes, comparing genotype 4/4 with the combined group composed of genotype 4/5 and 5/5, we obtained a statistical analysis of significant value. These results are in line with previous studies that linked a depressive onset, a tendency in our study for 4/4 genotype carriers and not sustained by statistical evidence, with a higher number of depressive episodes (Daban et al. 2006).

The major limitations of our study rely on the limited number of subjects taken into consideration, along with the relative reliability of the age of onset parameter, since patients may often not recollect precisely the age of the disease's manifestation. Further studies may need samples larger and more homogeneous in terms of both samples and methods of analysis. Finally, multicenter studies could clarify whether effective environmental factors influence *PER3* VNTR genotype functions in the context of bipolar disorder regarding age of onset.

#### Abbreviations

VNTR	Variable number of tandem repeats
ANCOVA	Analysis of covariance
SCN	Suprachiasmatic nucleus
ipRGC	internal photosensitive retinal ganglion cells
DSPD	Delayed sleep phase disorder

#### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40345-024-00346-7>.

Supplementary Material 1

#### Acknowledgements

We would like to thank the patients for their cooperation.

#### Author contributions

Conceptualization and design were performed by T.B., P.R., M.P. and B.S. Data extraction was conducted by T.B. and verified by P.R., M.P., V.S. and C.D.A. screened citations for inclusion. T.B. and P.R. wrote the main manuscript text and T.B. and F.C. prepared Figs. 1, 2, 3, 4, 5, 6, 7 and 8; Tables 1, 2, 3 and 4. T.B., P.R. and F.P. developed methodology, formal analysis, and data curation. All authors contributed equally to the article. All authors read and approved the final manuscript.

#### Funding

None.

#### Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

#### Declarations

##### Ethics approval and consent to participate

The study was approved by the institutional review board of the Medical Faculty of the Technische Universität Dresden (IRB00001473 and IORG0001076). Written informed consent was obtained from all patients willing to participate in the study after a detailed description of the study's aim and procedures. This study adheres to the Declaration of Helsinki and its later amendments.

##### Consent for publication

Not applicable.

##### Competing interests

The authors declare no competing interests.

Received: 17 November 2023 / Accepted: 18 June 2024

Published online: 11 July 2024

#### References

- Abreu T, Bragança M. The bipolarity of light and dark: a review on bipolar disorder and circadian cycles. *J Affect Disord*. 2015;185:219–29. <https://doi.org/10.1016/j.jad.2015.07.017>.
- Alexander M, Burch JB, Steck SE, et al. Case-control study of the PERIOD3 clock gene length polymorphism and colorectal adenoma formation. *Oncol Rep*. 2015;33(2):935–41. <https://doi.org/10.3892/or.2014.3667>.
- Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene *Per3* is linked to delayed sleep phase syndrome and extreme diurnal preference. *Sleep*. 2003;26(4):413–5. <https://doi.org/10.1093/sleep/26.4.413>.
- Archer SN, Schmidt C, Vandewalle G, Dijk DJ. Phenotyping of *PER3* variants reveals widespread effects on circadian preference, sleep regulation, and health. *Sleep Med Rev*. 2018;40:109–26. <https://doi.org/10.1016/j.smrv.2017.10.008>.
- Bauer M, Glenn T, Alda M, et al. Impact of sunlight on the age of onset of bipolar disorder. *Bipolar Disord*. 2012;14(6):654–63. <https://doi.org/10.1111/j.1399-5618.2012.01025.x>.
- Bellivier F, Golmard JL, Henry C, Leboyer M, Schürhoff F. Admixture analysis of age at onset in bipolar I affective disorder. *Arch Gen Psychiatry*. 2001;58(5):510–2. <https://doi.org/10.1001/archpsyc.58.5.510>.
- Benedetti F, Dallaspezia S, Colombo C, Pirovano A, Marino E, Smeraldi E. A length polymorphism in the circadian clock gene *Per3* influences age at onset of bipolar disorder. *Neurosci Lett*. 2008;445(2):184–7. <https://doi.org/10.1016/j.neulet.2008.09.002>.
- Bollettini I, Melloni EM, Aggio V, et al. Clock genes associate with white matter integrity in depressed bipolar patients. *Chronobiol Int*. 2017;34(2):212–24. <https://doi.org/10.1080/07420528.2016.1260026>.
- Brasil Rocha PM, Campos SB, Neves FS, da Silva Filho HC. Genetic Association of the PERIOD3 (*Per3*) clock gene with bipolar disorder. *Psychiatry Investig*. 2017;14(5):674–80. <https://doi.org/10.4306/pi.2017.14.5.674>.
- Chellappa SL, Viola AU, Schmidt C, et al. Human melatonin and alerting response to blue-enriched light depend on a polymorphism in the clock gene *PER3*. *J Clin Endocrinol Metab*. 2012;97(3):E433–7. <https://doi.org/10.1210/jc.2011-2391>.
- Chellappa SL, Viola AU, Schmidt C, et al. Light modulation of human sleep depends on a polymorphism in the clock gene *Period3*. *Behav Brain Res*. 2014;271:23–9. <https://doi.org/10.1016/j.bbr.2014.05.050>.
- Daban C, Colom F, Sanchez-Moreno J, García-Amador M, Vieta E. Clinical correlates of first-episode polarity in bipolar disorder. *Compr Psychiatry*. 2006;47(6):433–7. <https://doi.org/10.1016/j.comppsy.2006.03.009>. Epub 2006 May 26. PMID: 17067865.
- Dai H, Zhang L, Cao M, et al. The role of polymorphisms in circadian pathway genes in breast tumorigenesis. *Breast Cancer Res Treat*. 2011;127(2):531–40. <https://doi.org/10.1007/s10549-010-1231-2>.
- Dallaspezia S, Lorenzi C, Pirovano A, Colombo C, Smeraldi E, Benedetti F. Circadian clock gene *Per3* variants influence the postpartum onset of bipolar

- disorder. *Eur Psychiatry*. 2011;26(3):138–40. <https://doi.org/10.1016/j.eurpsy.2010.11.009>.
- Dallaspezia S, Locatelli C, Lorenzi C, Pirovano A, Colombo C, Benedetti F. Sleep homeostatic pressure and PER3 VNTR gene polymorphism influence antidepressant response to sleep deprivation in bipolar depression. *J Affect Disord*. 2016;192:64–9. <https://doi.org/10.1016/j.jad.2015.11.039>.
- Dick R. 2012. Scotobiology. In: Environmental impact of light pollution and its abatement. *Journal of the Royal Astronomical Society of Canada*. [http://www.rasc.ca/sites/default/files/LPA\\_Special\\_Issue\\_LR.pdf](http://www.rasc.ca/sites/default/files/LPA_Special_Issue_LR.pdf) [Google Scholar].
- Drake CL, Belcher R, Howard R, Roth T, Levin AM, Gumenyuk V. Length polymorphism in the period 3 gene is associated with sleepiness and maladaptive circadian phase in night-shift workers. *J Sleep Res*. 2015;24(3):254–61. <https://doi.org/10.1111/jsr.12264>.
- Ebisawa T, Uchiyama M, Kajimura N, et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. *EMBO Rep*. 2001;2(4):342–6. <https://doi.org/10.1093/embo-reports/kve070>.
- Etain B, Dumaine A, Bellivier F, et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. *Hum Mol Genet*. 2012;21(18):4030–7. <https://doi.org/10.1093/hmg/dds227>.
- Foster RG. Neurobiology: bright blue times. *Nature*. 2005;433:698–9. [Crossref], [PubMed], [Web of Science \*], [Google Scholar].
- Goodwin FK, Jamison KR. Manic Depressive illness. *Bipolar disorders and recurrent depression*. New York: Oxford University Press; 2007. Part II Clinical Studies; Chap. 4 Course and Outcome; Age at onset p.121.
- Grigoriou-Serbanescu M, Martinez M, Nöthen MM, et al. Different familial transmission patterns in bipolar I disorder with onset before and after age 25. *Am J Med Genet*. 2001;105(8):765–73. <https://doi.org/10.1002/ajmg.10047>.
- Guess J, Burch JB, Ogooussan K, et al. Circadian disruption, Per3, and human cytokine secretion. *Integr Cancer Ther*. 2009;8(4):329–36. <https://doi.org/10.1177/1534735409352029>.
- Hamshere ML, Gordon-Smith K, Forty L, et al. Age-at-onset in bipolar-I disorder: mixture analysis of 1369 cases identifies three distinct clinical sub-groups. *J Affect Disord*. 2009;116(1–2):23–9. <https://doi.org/10.1016/j.jad.2008.10.021>.
- Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. *Science*. 2002;295(5557):1065–70. <https://doi.org/10.1126/science.1069609>.
- Kalman JL, Papiol S, Forstner AJ, et al. Investigating polygenic burden in age at disease onset in bipolar disorder: findings from an international multicentric study. *Bipolar Disord*. 2019;21(1):68–75. <https://doi.org/10.1111/bdi.12659>.
- Karthikeyan R, Marimuthu G, Ramasubramanian C, et al. Association of Per3 length polymorphism with bipolar I disorder and schizophrenia. *Neuropsychiatr Dis Treat*. 2014;10:2325–30. <https://doi.org/10.2147/ndt.s73765>.
- Lax P, Ortuño-Lizarán I, Maneu V, Vidal-Sanz M, Cuenca N. Photosensitive melanopsin-containing retinal ganglion cells in Health and Disease: implications for circadian rhythms. *Int J Mol Sci*. 2019;20(13):3164. <https://doi.org/10.3390/ijms20133164>. Published 2019 Jun 28.
- Leboyer M, Henry C, Paillere-Martinot ML, Bellivier F. Age at onset in bipolar affective disorders: a review. *Bipolar Disord*. 2005;7(2):111–8. <https://doi.org/10.1111/j.1399-5618.2005.00181.x>.
- Leocadio-Miguel MA, Carneiro BT, Ximenes-da-Silva A, Caumo W, Grassi-Kassisse D, Pedrazzoli M. PER3 gene regulation of sleep-wake behavior as a function of latitude. *Sleep Health*. 2018;4(6):572–8. <https://doi.org/10.1016/j.sleh.2018.10.002>.
- Manchia M, Lampus S, Chillotti C, et al. Age at onset in sardinian bipolar I patients: evidence for three subgroups. *Bipolar Disord*. 2008;10(3):443–6. <https://doi.org/10.1111/j.1399-5618.2007.00572.x>.
- Mansour HA, Wood J, Chowdari KV, et al. Circadian phase variation in bipolar I disorder. *Chronobiol Int*. 2005;22(3):571–84. <https://doi.org/10.1081/CBI-200062413>.
- Mansour HA, Wood J, Logue T, et al. Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. *Genes Brain Behav*. 2006;5(2):150–7. <https://doi.org/10.1111/j.1601-183X.2005.00147.x>.
- Matsumura R, Akashi M. Role of the clock gene Period3 in the human cell-autonomous circadian clock. *Genes Cells*. 2019;24(2):162–71. <https://doi.org/10.1111/gtc.12664>.
- Melo MCA, Abreu RLC, Linhares Neto VB, de Bruin PFC, de Bruin VMS. Chronotype and circadian rhythm in bipolar disorder: a systematic review. *Sleep Med Rev*. 2017;34:46–58. <https://doi.org/10.1016/j.smrv.2016.06.007>.
- Nievergelt CM, Kripke DF, Barrett TB, et al. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2006;141B(3):234–41. <https://doi.org/10.1002/ajmg.b.30252>.
- Pereira DS, Tufik S, Louzada FM, Benedito-Silva AA, Lopez AR, Lemos NA, Korczak AL, D'Almeida V, Pedrazzoli M. Association of the length polymorphism in the human Per3 gene with the delayed sleep-phase syndrome: does latitude have an influence upon it? *Sleep*. 2005;28(1):29–32. PMID: 15700718.
- Post RM, Leverich GS, Kupka R, et al. Increased parental history of bipolar disorder in the United States: association with early age of onset. *Acta Psychiatr Scand*. 2014;129(5):375–82. <https://doi.org/10.1111/acps.12208>.
- Propper L, Ortiz A, Slaney C, et al. Early-onset and very-early-onset bipolar disorder: distinct or similar clinical conditions? *Bipolar Disord*. 2015;17(8):814–20. <https://doi.org/10.1111/bdi.12346>.
- Ritter PS, Höfler M, Wittchen HU, et al. Disturbed sleep as risk factor for the subsequent onset of bipolar disorder—data from a 10-year prospective-longitudinal study among adolescents and young adults. *J Psychiatr Res*. 2015;68:76–82. <https://doi.org/10.1016/j.jpsy.2015.06.005>.
- Ritter P, Wieland F, Skene DJ, Pfennig A, Weiss M, Bauer M, Severus E, Güldner H, Sauer C, Soltmann B, Neumann S. Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls. *J Psychiatry Neurosci*. 2019;44(6):190005. <https://doi.org/10.1503/jpn.190005>. Epub ahead of print. PMID: 31509363.
- Ritter P, Wieland F, Skene DJ, Pfennig A, Weiss M, Bauer M, Severus E, Güldner H, Sauer C, Soltmann B, Neumann S. Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls. *J Psychiatry Neurosci*. 2020;45(2):79–87. <https://doi.org/10.1503/jpn.190005>. PMID: 32096617; PMCID: PMC7828907.
- Roenneberg T, Kumar CJ, Merrow M. The human circadian clock entrains to sun time. *Curr Biol*. 2007;17(2):R44–5. <https://doi.org/10.1016/j.cub.2006.12.011>.
- Subramanian K, Sarkar S, Kattimani S, Rajkumar RP. Influence of age at onset on the course and outcome of bipolar I disorder: findings from a retrospective study. *Asian J Psychiatr*. 2018;31:135–6. <https://doi.org/10.1016/j.ajp.2018.01.015>.
- Van Meter AR, Burke C, Youngstrom EA, Faedda GL, Correll CU. The Bipolar Prodrome: Meta-Analysis of Symptom Prevalence Prior to Initial or Recurrent Mood Episodes. *J Am Acad Child Adolesc Psychiatry*. 2016;55(7):543–55. <https://doi.org/10.1016/j.jaac.2016.04.017>. Epub 2016 May 11. PMID: 27343882.
- Vandewalle G, Archer SN, Guillaume C, et al. Effects of light on cognitive brain responses depend on circadian phase and sleep homeostasis. *J Biol Rhythms*. 2011;26(3):249–59. <https://doi.org/10.1177/0748730411401736>.
- Viena TD, Gobin CM, Fins AI, Craddock TJ, Tartar A, Tartar JL. A PER3 polymorphism interacts with sleep duration to influence transient Mood States in Women. *J Circadian Rhythms*. 2016;14:3. <https://doi.org/10.5334/jcr.135>. Published 2016 Mar 10.
- Wirth MD, Burch JB, Hébert JR, et al. Case-control study of breast cancer in India: role of PERIOD3 clock gene length polymorphism and chronotype. *Cancer Invest*. 2014;32(7):321–9. <https://doi.org/10.3109/07357907.2014.919305>.
- Yamaguchi M, Kotani K, Tsuzaki K, et al. Circadian rhythm genes CLOCK and PER3 polymorphisms and morning gastric motility in humans. *PLoS ONE*. 2015;10(3):e0120009. <https://doi.org/10.1371/journal.pone.0120009>. Published 2015 Mar 16.
- Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. *Cancer Epidemiol Biomarkers Prev*. 2005;14(1):268–70.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)